ARCHIVES

FDA, CMS Take Second Look at Drugs Given “Accelerated” Approval for Cancer

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

ONS Membership Still Climbing, Soars over 15,000

June 23, 1989

Rituximab Maintenance Improves Survival In Relapse

February 27, 2009

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

August 12, 2011

“One Time Offer” On Comprehensiveness Approved By NCAB

September 22, 1989

Broder Hopes To Help “Fundable: Centers, Stops Short Of Promising Compliance With All IOM Points

May 5, 1989